Hello again:
Your comments, I believe, are valid. But remember. The test is already approved for screening in Japan. Very big country. Very big population of bladder cancer patients and people at risk (they all smoke, a huge risk factor for bladder CA).
The value of the the yen against the dollar may be a negative, but, even so, who cares. If there's business to be done, it will be done. The dollar/yen exchange problem is relative. Not absolute. Huge volume can overcom this. And when the ratio changes, which it will I presume at some future date, it will be even better.
However, this brings up yet another problem. One of production. I am not at all sure that this company, with all their money woes, can ramp up to meet demand. This could be as bad as not having a good product. The current facility is only good for about 10 million dollars in revenue (at lease according to Steve Chubb last year). At ten dollars a pop for the test that means they can produce a million tests per year. If the test catches on in Japan quickly (which it might with Konica pushing it) the company could be easily swamped and not meet demand. I assume that Konica would help them out under this circumstance but, remember, this is a biological product produced in mice. It takes tiime to make it. Potential problem.
What the company needs desperately is verification of industry acceptance. Read that partner for the cervical cancer screen NMP. If that occurs anytime soon, a serious increase in share price could be imminent. However, with no insiders buying, little "news" from the company, a lack of response to the questions raised by folks like you and me (and probably many others) this company is dead in the water. A lack of early second quarter reporting also indicates that revenues won't be terrific for this quarter. I would bet 400K, at best, for NMP22 sales.
If Steve Chubb or any PR people are reading these comments, how about an honest, straight forward response. What have they got to lose compared to what has been lost already. I won't hold my breath waiting. They are not the type of people who would responod - read that primarily Mr. Corbett - he'd rather sell.
The clock continues to tick. Just more time for future competitors to use to make their products.
topvest |
